Pharmaceutical Nanotechnology : (Record no. 120702)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11324nam a22005533i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC4756292 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240729130954.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2017 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9783527800674 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9783527340545 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC4756292 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL4756292 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr11309810 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaONFJC)MIL974568 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)964698761 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RM301.25.P437 2017 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.19 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Cornier, Jean. |
| 245 10 - TITLE STATEMENT | |
| Title | Pharmaceutical Nanotechnology : |
| Remainder of title | Innovation and Production. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Newark : |
| Name of producer, publisher, distributor, manufacturer | John Wiley & Sons, Incorporated, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2017. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2017. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (807 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 490 1# - SERIES STATEMENT | |
| Series statement | Applications of Nanotechnology Series |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Pharmaceutical Nanotechnology: Innovation and Production -- Series Editor Preface -- About the Series Editor -- Contents -- Foreword -- Industrial Requirement on Nanopharmacy Research -- Introduction -- Part One: Entry to the Nanopharmacy Revolution -- 1: History: Potential, Challenges, and Future Development in Nanopharmaceutical Research and Industry -- 1.1 Nanopharmaceuticals in Cancer Therapy -- 1.2 Nanoparticles Actively Using the Host Machinery -- 1.3 Nanopharmaceuticals for Oral Administration and Long-Acting Injectable Therapy -- 1.4 Bridging Future Nanomedicines to Commercialization -- 1.5 Future Outlook -- Acknowledgments -- References -- 2: Nanoscale Drugs: A Key to Revolutionary Progress in Pharmacy and Healthcare -- 2.1 Introduction -- 2.1.1 Setting the Stage -- 2.1.2 Definition and Size Aspects -- 2.1.3 Nanopharmacy: Interdisciplinary Medicine -- 2.2 Nanopharmacy Concepts to Improve the Safety and Efficacy of Medicines -- 2.2.1 Overcoming the Solubility Barrier -- 2.2.2 Controlling Drug Release -- 2.2.2.1 Sustained Release -- 2.2.2.2 Stimuli-Responsive Release -- 2.2.3 Overcoming Biological Barriers -- 2.2.3.1 Epithelial-Endothelial Barriers -- 2.2.3.2 Noncellular Barriers -- 2.2.4 Targeting -- 2.2.4.1 Active Targeting -- 2.2.4.2 Passive Targeting -- 2.3 Technical Realization of Nanopharmaceuticals -- 2.3.1 Nanosized APIs -- 2.3.2 Organic Nanocarriers -- 2.3.2.1 Lipid-Based Nanocarriers -- 2.3.2.2 Polymer-Based Nanocarriers -- 2.3.2.3 Protein-Based Nanoparticles -- 2.3.3 Inorganic Nanoparticles -- 2.4 Safety of Nanopharmaceuticals -- 2.5 Present and Future of Nanopharmacy -- References -- 3: The Emergence of Nanopharmacy: From Biology to Nanotechnology and Drug Molecules to Nanodrugs -- 3.1 Introduction -- 3.2 First Generation of Nanopharmaceuticals: From Drug Molecules to Nanodrugs. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 3.2.1 Making New Therapies Happen: The Example of Nucleic Acid Therapeutics -- 3.2.1.1 Making Nanodrugs Smarter: Multifunctional Nanodrugs -- 3.3 Conclusion -- References -- 4: Understanding and Characterizing Functional Properties of Nanoparticles -- 4.1 Introduction -- 4.1.1 Key Concepts: Size Matters, Biological Interactions -- 4.1.2 Link Between Material Properties and Characterization for Differing Timescales of Biological Interaction -- 4.1.2.1 Early Times -- 4.1.2.2 Degradation of Surface -- 4.1.2.3 Long Timescales -- 4.1.2.4 Priorities -- 4.2 The Approach to Characterization -- 4.2.1 The Nature of Early-Stage Biological Recognition -- 4.2.1.1 Epitope and Recognition Motif Mapping -- 4.2.1.2 Forces, Dynamics, and Other Processes at Bio-Nano interface -- 4.2.2 The Nature of the Intracellular Bio-Nano Interface -- 4.2.3 The Future of the Bio-Nano Interface, Bionanoscience, and Nanomedicine -- References -- 5: Omics-Based Nanopharmacy: Powerful Tools Toward Precision Medicine -- 5.1 Introduction -- 5.2 Precision Medicine -- 5.2.1 Precision Oncology -- 5.2.2 Therapeutic mAbs -- 5.2.3 Therapeutic Small-Molecules Inhibitors -- 5.2.4 Chimeric Antigen Receptors (CARs) -- 5.3 "OMICS" - New Era in Understanding Pathology -- 5.3.1 Next-Generation Sequencing (NGS) -- 5.3.2 The Identification of "Clear-Cut" Biomarkers Using State-of-the-Art Proteomics -- 5.3.3 Personal OMICS Profiling -- 5.3.4 Single-Cell Sequencing -- 5.4 Nanomedicine -- 5.4.1 Personalized Oncology Using Nanomedicine -- 5.4.1.1 Passive Tissue Targeting vs. Active Cellular Targeting -- 5.4.2 RNAi: A powerful Approach for Cancer Personalized Therapy -- 5.5 Future Outlook -- Acknowledgments -- References -- Part Two: Fundamentals of Nanotechnology in Pharmacy -- 6: Nanostructures in Drug Delivery -- 6.1 Introduction -- 6.2 Nanocarrier Classification -- 6.2.1 Inorganic Nanostructures. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 6.2.2 Organic Nanostructures -- 6.2.2.1 Drug Nanocrystals -- 6.2.2.2 Matrix Systems -- 6.2.2.3 Vesicular Systems -- 6.3 Drug Loading and Release -- 6.3.1 Hydrophobic Drugs -- 6.3.2 Hydrophilic Drugs -- 6.3.3 Macromolecular Drugs -- 6.4 General Discussion and Conclusions -- References -- 7: Characterization Methods: Physical and Chemical Characterization Techniques -- 7.1 The Need for Nanomedicine-Specific Characterization -- 7.2 The Assay Cascade: From Basic Properties to Complex Interactions -- 7.3 Physicochemical Characterization of Pristine Nanoparticles -- 7.3.1 Size, Size Distribution, and Topology -- 7.3.1.1 Batch Particle Sizing Techniques -- 7.3.1.2 Single Particle Sizing Techniques -- 7.3.1.3 Separation- and Fractionation-Based Sizing Techniques -- 7.3.2 Surface Characteristics and Functionalization -- 7.3.2.1 Zeta (ζ) Potential -- 7.3.2.2 Chemical Surface Functionalization and Targeting -- 7.3.3 Composition and Purity -- 7.4 Characterization of Nanoparticles in the Biological Environment -- 7.4.1 Sterility and Endotoxin -- 7.4.2 Surface Adsorption: the Protein Corona -- 7.4.3 Drug Release -- 7.5 Conclusions and Future Outlook -- References -- 8: Nanoparticle Characterization Methods: Applications of Synchrotron and Neutron Radiation -- 8.1 Advanced Characterization: Synchrotron Light and Neutron Sources -- 8.2 Application Examples -- 8.2.1 Synchrotron Micro-X-ray Fluorescence and Micro-X-ray Absorption Spectroscopy -- 8.2.2 Pair Distribution Function -- 8.2.3 Small-angle X-ray Scattering -- 8.2.4 Small-Angle Neutron Scattering and Neutron Reflectometry -- 8.3 Going Beyond Characterization Using Synchrotron X-rays: Nanoparticles for Diagnostic and Therapeutic Approaches -- 8.4 Looking Ahead and Conclusions -- Acknowledgments -- References -- 9: Overview of Techniques and Description of Established Processes -- 9.1 Introduction. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 9.2 Processing of Liquid Drug Carrier Formulations -- 9.2.1 Colloidal Lipid Emulsions -- 9.2.1.1 General Aspects and Composition -- 9.2.1.2 Preparation Process of Intravenous Fat Emulsions -- 9.2.1.3 Preparation of the Adjuvant Emulsion MF59 -- 9.2.2 Liposomes -- 9.2.2.1 General Aspects and Composition -- 9.2.2.2 Preparation of Liposomal Dispersions -- 9.2.2.3 Drug Incorporation into Liposomes and Other Colloidal Lipid Structures -- 9.2.2.4 DepotFoam® Technology -- 9.2.2.5 Sterilization of Liposomes -- 9.2.2.6 Drying of Liposomal Dispersions -- 9.2.3 Polymeric Nanoparticles -- 9.2.3.1 General Aspects -- 9.2.3.2 Abraxane® -- 9.3 Drug Nanoparticles and Process Chains to Solid Formulations -- 9.3.1 Drug Particle Size-Determining Processes -- 9.3.1.1 Comminution Processes (Top-Down Methods) -- 9.3.1.2 Bottom-Up Processes -- 9.3.1.3 Hybrid/Combinative Methods -- 9.3.2 Drying Methods and Further Processing -- 9.3.2.1 Freeze-Drying -- 9.3.2.2 Spray-Drying -- 9.3.2.3 Spray-Coating, Granulation, and Pelletization -- 9.3.2.4 Other Conversion Methods -- 9.3.3 Marketed Products Containing Drug Nanoparticles -- 9.3.3.1 Rapamune® -- 9.3.3.2 Emend® -- 9.4 Industrial Status and Framework -- 9.5 Perspectives for Academia, Industry, and Regulatory Authorities -- References -- 10: Nanopharmacy: Exploratory Methods for Polymeric Materials -- 10.1 Introduction -- 10.2 Rationale for the Use of Polymers in Nanomedicines -- 10.3 Polymer Structures and Properties -- 10.3.1 Polymer Morphology -- 10.3.2 Polymer Structures for Drug Delivery - Micelles and Vesicles -- 10.4 Formulation of Copolymers into Micelles, Vesicles, and Nanoparticles -- 10.4.1 Investigational Formulations - Stimuli-Responsive Polymers -- 10.5 Conjugation of Polymers to Drugs and Proteins -- 10.5.1 Polymer-drug Conjugates -- 10.5.2 PEG-Protein Conjugates -- 10.5.3 Properties of PEGylated Proteins. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 10.5.4 Preparation of PEGylated Proteins -- 10.5.5 Moving Beyond Protein PEGylation -- 10.6 Recent Advances in Polymer Synthesis for Therapeutic Applications -- 10.6.1 Biodegradable Polymers for Nanomedicines -- 10.6.2 Classification of Biodegradable Polymers -- 10.6.2.1 Naturally Occurring Biodegradable Polymers for Nanomedicine -- 10.6.2.2 Synthetic Biodegradable Polymers for Nanomedicine -- 10.6.3 Mechanisms of Polycondensation Reactions -- 10.6.3.1 Fischer Esterification -- 10.6.3.2 Transesterification -- 10.6.4 Ring-Opening Polymerization -- 10.6.4.1 Anionic ROP -- 10.6.4.2 Cationic ROP -- 10.6.4.3 Coordination-Insertion ROP -- 10.6.5 Examples of Synthetic Polyesters as Investigational Nanomedicines -- 10.6.5.1 Poly(caprolactone) -- 10.6.5.2 Poly(anhydrides) -- 10.6.5.3 Poly(trimethylene Carbonate) -- 10.6.5.4 Polyesters in Development -- 10.6.5.5 Poly(esters) of Lactide and Glycolide -- 10.7 Controlled Radical Polymerization (CRP) -- 10.7.1 Atom Transfer Radical Polymerization (ATRP) -- 10.7.2 Reversible Addition Fragmentation Chain Transfer (RAFT) Polymerization -- 10.8 Concluding Remarks -- References -- 11: Overview and Presentation of Exploratory Methods for Manufacturing Nanoparticles/"Inorganic Materials -- 11.1 Introduction -- 11.2 Gold NPs -- 11.2.1 Different Shapes and Optical Properties -- 11.2.2 Conjugated (Covalent and Noncovalent) -- 11.2.3 Polymer/Polyelectrolyte Coating -- 11.2.4 Lipids -- 11.2.5 Composite -- 11.3 Magnetic NPs -- 11.3.1 Synthesis -- 11.3.2 Stabilization/Protection of Magnetic NPs -- 11.3.3 Hybrid Magnetic Nanosystem for Delivery -- 11.4 Metal Oxide NPs -- 11.4.1 Silica/Silicon -- 11.4.2 Calcium Phosphate, Hydroxyapatite -- 11.4.3 Others: Titanium Oxide and Aluminum Oxide -- 11.5 Others (Silver, Quantum Dots, and Lanthanides) -- 11.6 Conclusion and Perspective -- Acknowledgment -- References. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 12: Scale-Up and cGMP Manufacturing of Nanodrug Delivery Systems for Clinical Investigations. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug development. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Owen, Andrew. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kwade, Arno. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Van de Voorde, Marcel. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Cornier, Jean |
| Title | Pharmaceutical Nanotechnology |
| Place, publisher, and date of publication | Newark : John Wiley & Sons, Incorporated,c2017 |
| International Standard Book Number | 9783527340545 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
| Uniform title | Applications of Nanotechnology Series |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=4756292">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=4756292</a> |
| Public note | Click to View |
No items available.